CL King upgraded shares of Dr.Reddy’s Laboratories (NYSE:RDY) from a neutral rating to a buy rating in a research note released on Monday, February 4th, The Fly reports.
A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Dr.Reddy’s Laboratories from a buy rating to a hold rating in a report on Friday, January 18th. Citigroup downgraded shares of Dr.Reddy’s Laboratories from a neutral rating to a sell rating in a research note on Thursday, January 17th. Finally, ValuEngine raised shares of Dr.Reddy’s Laboratories from a sell rating to a hold rating in a research report on Friday, October 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. Dr.Reddy’s Laboratories has a consensus rating of Hold and an average price target of $43.00.
NYSE RDY traded up $0.01 during trading hours on Monday, reaching $37.69. 215,287 shares of the company were exchanged, compared to its average volume of 241,543. The company has a market capitalization of $6.12 billion, a PE ratio of 37.32 and a beta of 0.16. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.26 and a current ratio of 1.81. Dr.Reddy’s Laboratories has a 1 year low of $28.13 and a 1 year high of $40.20.
Dr.Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Friday, February 1st. The company reported $0.41 EPS for the quarter. Dr.Reddy’s Laboratories had a net margin of 11.64% and a return on equity of 13.16%. The company had revenue of $535.42 million during the quarter. As a group, analysts forecast that Dr.Reddy’s Laboratories will post 1.52 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in RDY. Private Capital Group LLC increased its position in shares of Dr.Reddy’s Laboratories by 209.2% during the 4th quarter. Private Capital Group LLC now owns 739 shares of the company’s stock valued at $28,000 after purchasing an additional 500 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in Dr.Reddy’s Laboratories in the 4th quarter worth approximately $34,000. Advisor Group Inc. increased its holdings in Dr.Reddy’s Laboratories by 147.2% in the 4th quarter. Advisor Group Inc. now owns 979 shares of the company’s stock worth $37,000 after acquiring an additional 583 shares in the last quarter. Lindbrook Capital LLC purchased a new stake in Dr.Reddy’s Laboratories in the 4th quarter worth approximately $48,000. Finally, grace capital increased its holdings in Dr.Reddy’s Laboratories by 100.0% in the 4th quarter. grace capital now owns 3,000 shares of the company’s stock worth $113,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors own 11.43% of the company’s stock.
Dr.Reddy’s Laboratories Company Profile
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.
Read More: Diversification For Individual Investors
Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.